SCANCELL HOLDINGS PLC
SCLP | IL
Overview
Corporate Details
- ISIN(s):
- GB00B63D3314 (+2 more)
- LEI:
- 2138008RXEG856SNP666
- Country:
- United Kingdom
- Address:
- BELLHOUSE BUILDING, OX4 4GA OXFORD
- Website:
- https://www.scancell.co.uk/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Scancell Holdings PLC is a clinical-stage biopharmaceutical company focused on the discovery and development of immunotherapies for cancer and infectious diseases. The company advances a pipeline of therapeutic vaccines and monoclonal antibodies based on its proprietary technology platforms, including ImmunoBody®, Moditope®, and AvidiMab™. Its core focus is on creating potent, safe, and accessible "off-the-shelf" therapies that stimulate long-lasting, tumor-specific immunity. Scancell's advanced therapeutic vaccine programs, SCOPE and ModiFY, have shown promising efficacy in clinical trials for treating hard-to-treat cancers, such as metastatic melanoma and a broad range of solid tumors, addressing significant unmet medical needs.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for SCANCELL HOLDINGS PLC.
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-08 13:31 |
Director's Dealing
Director Dealing
|
English | 22.0 KB | |
| 2025-08-04 11:23 |
Director's Dealing
Director/PDMR Shareholding
|
English | 22.7 KB | |
| 2025-07-22 08:00 |
Earnings Release
Strong Phase 2 data on iSCIB1+ in Melanoma
|
English | 20.8 KB | |
| 2025-07-16 08:00 |
Share Issue/Capital Change
Share Option Exercise
|
English | 13.6 KB | |
| 2025-06-25 08:00 |
Legal Proceedings Report
Scancell initiates new arm in SCOPE Phase 2 study
|
English | 18.2 KB | |
| 2025-02-20 08:00 |
Director's Dealing
Issue of share options
|
English | 41.5 KB | |
| 2025-02-17 08:00 |
Regulatory News Service
Scancell presenting at AACR IO conference
|
English | 19.6 KB | |
| 2025-01-30 08:00 |
Interim Report
Interim Results
|
English | 250.6 KB | |
| 2025-01-23 08:00 |
Report Publication Announcement
Notice of Interim Results
|
English | 11.5 KB | |
| 2025-01-09 08:00 |
Regulatory News Service
Modi-1 Vaccine Achieves Early Clinical Validation
|
English | 15.7 KB | |
| 2024-12-09 12:41 |
Share Issue/Capital Change
Result of Retail Offer and Total Voting Rights
|
English | 26.7 KB | |
| 2024-12-05 13:39 |
Share Issue/Capital Change
Result of Placing and Subscription
|
English | 64.8 KB | |
| 2024-12-04 19:03 |
Share Issue/Capital Change
Retail Offer for up to £1 million
|
English | 31.7 KB | |
| 2024-12-04 18:59 |
Share Issue/Capital Change
Proposed fundraise in excess of £8.5 million
|
English | 169.9 KB | |
| 2024-12-04 08:00 |
Regulatory News Service
Second Commercial License Agreement with Genmab
|
English | 16.5 KB |
Automate Your Workflow. Get a real-time feed of all SCANCELL HOLDINGS PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for SCANCELL HOLDINGS PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
